Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation up

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Mar 16, 2022 9:58pm

124 Views

Post# 34520658

RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation up

LouisW wrote:
What does dash line box mean?

Those are the patient numbers who also took that dose. You'll notice that patient #2 took at least 4 cycles. Maybe more because Thera didn't put dashed boxes after that. Patients stop the trial after progression, so likely patient 2 would at least have had some signal of efficacy or he/she would not have made it that far. Furthermore patient #2 started at 60mg/m2.

<< Previous

Bullboard Posts

Next >>

What is the gold outlook for the rest of 2024?